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Autologous saphenous vein remains the conduit
of choice for infrainguinal bypass grafting and con-
tinues to have widespread use for coronary bypass
grafting as well, despite its disappointing long-term
patency rate.1-3 Vein grafts undergo morphologic
and functional changes after insertion into the arte-
rial circulation, with significant alterations in
endothelial and smooth muscle cell activity leading
to the development of intimal hyperplasia.4,5
Because it is at the interface between the blood
and the vessel wall, normally functioning venous
endothelium is essential for vascular homeostasis. It
produces prostacyclin and nitric oxide (NO), both of
which are potent vasodilators as well as inhibitors of
platelet aggregation. Several studies have shown that
the dysfunctional endothelium of arterial vein grafts
manifests decreased ability to vasodilate in response
to endothelium-derived relaxing factor or NO,
reduced prostacyclin production, and decreased fibri-
nolytic activity.6-9 The endothelium is also involved
in modification to the structure of the vessel wall
through the secretion of factors that affect underly-
ing cellular growth and regression.10-14
Vascular endothelial growth factor (VEGF) is a
potent angiogenic growth factor that is endothelial
cell–specific and does not stimulate the proliferation
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of other cell types, such as fibroblasts or vascular
smooth muscle cells.15,16 Recent evidence suggests
that VEGF, in addition to stimulating angiogenesis,
also serves a repair/maintenance or survival func-
tion, modulating various aspects of endothelial cell
function. Ku et al.17 reported that VEGF induces
endothelium-dependent relaxation in canine coro-
nary arteries by stimulating endothelium-derived
relaxing factor/NO via a calcium-dependent mech-
anism. A previous study from our laboratory showed
that topical application of VEGF to balloon-injured
rat carotid arteries significantly accelerates reen-
dothelialization, thus abrogating the cascade of
events that leads to neointima formation and
restenosis.18 In addition, we demonstrated that
VEGF induces recovery of disturbed endothelium-
dependent flow in the rabbit ischemic hindlimb19
and that VEGF stimulates production of NO when
applied to quiescent, endothelium-intact vascular
segments from the thoracic aorta, pulmonary artery,
and inferior vena cava of New Zealand White rab-
bits.20 This response can be blocked by competitive
inhibition of nitric oxide synthase (NOS), suggest-
ing that the putative maintenance functions of
VEGF may include regulation of baseline synthesis,
release of endothelial cell NO, or both.
With this background, the present study was
designed to determine whether treatment of venous
conduits with VEGF before their implantation in the
arterial system would result in better preservation of
endothelial function, a reduction in intimal hyper-
plasia, or both.
MATERIAL AND METHODS
Forty-four male New Zealand White rabbits
weighing 3.0 to 3.5 kg were used in this experiment.
The experimental protocol for this project was
approved by the St. Elizabeth’s Medical Center
Institutional Animal Care and Use Committee and
complied with the Guide for the Care and Use of
Laboratory Animals (NIH publication No. 86-23,
revised 1985).
All rabbits were anesthetized with intramuscular
ketamine (50 mg/kg) and xylazine (5 mg/kg).
Operations were performed with an operating
microscope (STEMI SR, Zeiss, Germany) under
sterile conditions. After exposure through a midline
neck incision, a 2.5 cm segment of right external
jugular vein was carefully dissected and excised. The
venous conduit was flushed gently with heparinized
saline solution and then immersed for 20 minutes in
a 1 ml saline solution (0.9% saline with 0.1% albu-
min, heparin 5 IU) containing either 500 mg VEGF
(test group) or saline solution only (control group).
This dosage was arbitrarily selected in part on the
basis of previous demonstrations that 500 mg admin-
istered as an intraarterial bolus induced angiogenesis
in a rabbit model of hindlimb ischemia19 and 100 mg
administered topically promoted reendothelializa-
tion in the balloon-injured rat carotid artery.18 After
intravenous administration of 200 IU/kg heparin,
the ipsilateral common carotid artery was dissected.
The reversed venous conduit was anastomosed prox-
imally and distally to the artery in an end-to-side
manner with interrupted 8-0 polypropylene suture.
The common carotid artery was then ligated and
divided between the two anastomoses with 5-0
suture, and the wound was closed in layers.
Pathologic assessment. At 4 weeks after opera-
tion, eight rabbits from each group were anes-
thetized as above and perfusion-fixed in situ at 100
mm Hg with an initial infusion of heparinized saline
solution (1000 IU/L) followed by 100% methanol.
Tissues were embedded in paraffin and then
processed for light microscopy. Each graft was divid-
ed into a proximal, middle, and distal third. The his-
tologic sections were projected onto a digitizing
board (Summagraphics model MM1201, Fairfield,
Conn.), and the area of the intima and vessel cir-
cumference were measured with a computerized
sketching program (MacMeasure 1.9, National
Institute of Mental Health, Bethesda, Md.). The
intimal thickness was calculated as intimal area divid-
ed by mean intimal circumference.
Evans blue staining evaluation. At 3 days and
at 4 weeks after surgery, two rabbits from each
group received an intravenous injection via the ear
vein of 4 ml 0.5% Evans blue dye 30 minutes before
they were killed to allow macroscopic identification
of any areas of endothelial denudation.
Scanning electron microscopy. To further eval-
uate the endothelial morphologic features, both con-
trol and VEGF-treated vein grafts harvested 12 hours
and 4 weeks after surgery, along with normal jugular
veins (two rabbits each group), were studied using
scanning electron microscopy. Harvested vessels were
fixed overnight at 4° C in 2.5% glutaraldehyde in
0.13 mol/L cacodylate buffer, pH 7.4. After being
rinsed in buffer, specimens were postfixed in 1%
ostium tetroxide at 4° C for 1.5 hours, rinsed in
cacodylate buffer, and dehydrated through graded
concentrations of ethanol. The specimens were criti-
cal point–dried from 100% ethanol with liquid CO2.
The specimens were then bisected to expose the
luminal surface, mounted on stubs, and sputter-coat-
ed with gold. The samples were viewed and pho-
tographed at 10 kV with a scanning electron micro-
scope (model ISI-DS 130, International Scientific
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Instrument, Paramus, N.J.). Photomicrographs were
taken at 1.66 K magnifications.
Physiologic assessment. Four weeks after oper-
ation, the contralateral jugular veins and vein grafts
from six rabbits in each group were isolated, and a 5
mm ring was excised in situ from the middle seg-
ment of each graft as well as from the normal jugu-
lar vein. Each ring was immediately mounted
between two stainless steel hooks in an organ cham-
ber containing 10 ml Krebs-Henseleit solution
(NaCl, 118 mmol/L; KCl, 4.7 mmol/L; MgSO4,
1.2 mmol/L; CaCl2, 2.5 mmol/L; NaHCO3, 25
mmol/L; KH2PO4, 1.2 mmol/L; glucose, 11
mmol/L) at 37° C and were gassed with 95%
O2/5% CO2. One hook was fixed to the bottom of
the bath, and the other was connected to an FT-03
force transducer (Grass Instrument Co. Quincy,
Mass.) for recording of changes in force on a Grass
7D polygraph recorder. The vessels were placed
under 0.5 g tension and were allowed to equilibrate
in Krebs-Henseleit solution for 1 hour. After equili-
bration, the rings were progressively stretched to
optimal tension to establish a length/tension rela-
tionship by stretching and stimulation with 60
mmol/L KCl. The cumulative dose-response curve
to norepinephrine (10-9 to 10-4 mol/L) was deter-
mined. After maximal precontraction with norepi-
nephrine, relaxation in response to acetylcholine
(10-8 to 10-4 mol/L), calcium ionophore A23187
(10-8 to 104 mol/L), and sodium nitroprusside (10-8
to 10-4 mol/L) was measured. The vessels were
allowed to reequilibrate for 30 minutes between
each experimental run. All drugs were prepared daily
in distilled water except calcium ionophore A23187,
which was dissolved in dimethyl sulfoxide.
The isometric responses of the vessel rings were
converted to a percent of maximal response, and
these values were then plotted against the negative
logarithm of the agonist concentration to produce
dose-response curves. The maximal contractile
response of each ring to each agonist was expressed
in grams of force developed. Relaxation in response
to an agonist was expressed as the percentage
decrease from the maximal contractile tension devel-
oped to norepinephrine.
Reagents. The 165–amino acid heterodimeric
species of recombinant human VEGF (rhVEGF165)
purified from transfected Chinese hamster ovary
cells as previously described21 was the generous gift
of Genentech Inc., South San Francisco, Calif. The
purity of the material was assessed with a silver-
stained SDS PAGE gel and by the presence of a sin-
gle NH2-terminal amino acid sequence. Other
reagents were purchased from Sigma Chemical Co.
(St. Louis). Fresh stock solutions were prepared
immediately before each experiment.
Data and statistical analysis. All data were
evaluated with two-tailed, unpaired Student’s t test
or compared by one-way analysis of variance fol-
lowed by Fisher’s t test and expressed as the mean ±
SEM. A p value less than 0.05 was considered statis-
tically significant.
RESULTS
All grafts were patent at harvest. The endotheli-
um of both control and VEGF-treated vein grafts
harvested at 3 days and at 4 weeks after surgery
appeared grossly intact, demonstrating no obvious
Evans blue staining. Scanning electron microscopy
showed a continuous layer of endothelium on the
surface of normal jugular vein. Endothelial morpho-
logic features appeared to be minimally altered in all
grafts. Both control and VEGF-treated vein grafts
harvested 12 hours after implantation demonstrated
only localized areas of endothelial separation or loss.
These areas were covered with red blood cells and
platelets (Fig. 1, A and B). Four weeks after surgery,
scanning electron microscopy showed that both
control and VEGF-treated vein grafts were covered
by a continuous layer of endothelial cells, with min-
imal differences between groups (Fig. 1, C and D).
Intimal hyperplasia. Sample sections of a nor-
mal vein, a control vein graft, and a VEGF-treated
vein graft are shown in Fig. 2. The extent of intimal
thickening is seen to be significantly reduced in the
VEGF-treated graft. Because the internal elastic
lamina of transplanted jugular vein is often some-
what ill-defined by light microscopy, we did not
attempt to calculate the intimal/media ratio in this
study (Fig. 2).
Dimensional analysis of vein grafts from the
proximal, middle and distal segments was per-
formed. Because only slight differences were
observed between segments, the results were aver-
aged and are shown in Table I. VEGF-treated vein
grafts manifested a 23% reduction in intimal area
(0.76 ± 0.07 mm2 vs 0.98 ± 0.06 mm2; p = 0.028),
a 30% reduction in intimal thickness (62 ± 6 mm vs
89 ± 5 mm; p = 0.001), and a 13% increase in intimal
circumference (12.44 ± 0.50 mm vs 11.03 ± 0.34
mm; p = 0.013) when compared with control grafts.
Endothelial function studies. There were no
significant differences between the normal jugular
veins from the control and VEGF-treated groups in
the relaxation response to acetylcholine, calcium
ionophore A23187, and sodium nitroprusside, or in
the contractile response to norepinephrine. Normal
jugular veins and VEGF-treated vein grafts both
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relaxed to acetylcholine (receptor-mediated,
endothelium-dependent relaxation), whereas con-
trol vein grafts did not. Relaxation to acetylcholine,
expressed as percent change from the baseline after
maximal precontraction (100%), was 0 for control
grafts, 25% ± 9% for VEGF-treated grafts (p < 0.05
vs control grafts) and 59.5% ± 8% for normal veins
(Fig. 3, A). There was also a significant difference in
the maximal relaxation to calcium ionophore
A23187 (receptor-independent, endothelium inde-
pendent relaxation) in VEGF-treated vein grafts
compared with control grafts (172.3% ± 19.4% vs
122.5% ± 13.7%; p < 0.05) and jugular veins
(125.2% ± 7.8%; p < 0.05 vs VEGF-treated grafts;
Fig. 3, B). There was no significant difference in the
response to sodium nitroprusside (endothelium-
independent relaxation) in either control or VEGF-
treated vein grafts (control, 163.5% ± 19.4%; VEGF,
169.0% ± 19.1%; p > 0.05; Fig. 3, C). Both vein
grafts demonstrated significantly greater maximal
relaxation than did normal veins to this agonist.
DISCUSSION
VEGF, also known as vascular permeability fac-
tor, has been shown to be an endothelial cell–specif-
ic mitogen in vitro and an angiogenic growth factor
in vivo.15,22,23 Recent studies have demonstrated
that VEGF and its specific receptors, namely flk-1
(KDR) and flt-1, are abundantly expressed in
embryonic vasculature and hypoxic adult tis-
sues.24,25 The widespread expression and organ-spe-
cific distribution of VEGF mRNA and protein in
normal rat tissues support the concept that VEGF
may play a multifunctional role in the maintenance
of vascular function other than mediating vascular
growth.26,27 We previously demonstrated that direct
application of VEGF recombinant protein to the
denuded surface of the rat carotid artery accelerates
reendothelialization and leads to reduced neointimal
proliferation.18 More recently we showed that
VEGF stimulates production of NO when applied to
endothelium-intact vascular segments from the tho-
racic aorta, pulmonary artery, and inferior vena cava
of New Zealand White rabbits, inferring the pres-
ence of functional receptors on the quiescent
endothelium of the adult rabbit.20 That this
response is blocked by competitive inhibition of
NOS suggests that the putative maintenance func-
tions of VEGF may include regulation of baseline
synthesis, release of endothelial cell NO, or both,
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Fig. 1. Scanning electron micrographs taken of vein grafts harvested 12 hours after implanta-
tion in control (A) and VEGF-treated (B) groups and 4 weeks after implantation in control
(C) and VEGF-treated (D) groups. Photomicrographs were taken at 1.66K original magnifi-
cation.
supporting the notion of a “survival” or “mainte-
nance/repair” role for VEGF. Furthermore, the
demonstration that VEGF is capable of inducing
recovery of disturbed endothelium-dependent flow
in the rabbit ischemic hindlimb may reflect restored
NO production by endothelial cells that are initially
damaged by protracted ischemia in the collateral-
dependent limb.19
Some degree of intimal thickening in vein grafts
has been viewed as an adaptation to the switch from
venous to arterial hemodynamics.28,29 Increased
tangential stress (applied transversely to the vessel
wall) stimulates intimal thickening, whereas
increased shear stress (applied longitudinally) leads
to regression.30 Noris et al.13 have suggested that
this effect is modulated by transcriptional activation
of NO synthase as a result of the shear stress effect
on endothelial cells. The increased release of NO
could in turn induce intimal regression by several
mechanisms, including inhibition of smooth muscle
cell proliferation or even cell death, reduced expres-
sion of adhesion molecules that prevents recruit-
ment of inflammatory cells (a source of growth fac-
tors), or decreased collagen synthesis by smooth
muscle cells.30
Thus the essential role played by the endotheli-
um (in particular, its ability to release NO) in the
development of intimal hyperplasia and subsequent
vein graft occlusion is becoming increasingly recog-
nized. Loss of NO-mediated relaxation is character-
istic of intimal hyperplastic lesions.10,31 In addition
to its role as a vasodilator, studies32,33 have shown
that NO inhibits platelet adhesion and aggregation,
reduces neutrophil interaction with the endothelial
surface, and may neutralize superoxide radicals.
Furthermore, increased NO synthesis by the
endothelium may directly inhibit underlying smooth
muscle cell proliferation.31,33 As a result, a number
of studies have attempted to inhibit intimal thicken-
ing that is responsible for compromised arterial
patency by increasing the availability of NO. Davies
et al.34 showed that oral administration of the NO
precursor L-arginine 7 days before operation and
thereafter until harvest 28 days later significantly
reduced intimal hyperplasia and preserved endothe-
lium-derived relaxation in the rabbit vein graft
model. McNamara et al.35 demonstrated that L-argi-
nine inhibited intimal hyperplasia after balloon
angioplasty and that this effect was completely
blocked by the NO synthase (NOS) inhibitor L-
NAME. Recently, we showed that VEGF stimulates
NO release from quiescent rabbit and human vascu-
lar endothelium, and this response can also be
blocked by competitive inhibition of NOS.20 These
in vivo studies, in combination with the in vitro find-
ings, suggest that NO is at least in part responsible
for mediating the effect of VEGF on endothelial
function and intimal hyperplasia in this experiment.
In the present study, we demonstrate that a single
topical application of VEGF before implantation pre-
serves endothelium-dependent relaxation and reduces
intimal hyperplasia in a rabbit vein graft model. In
control vein grafts, receptor-mediated, endothelium-
dependent relaxation was lost and did not respond to
acetylcholine. In contrast, VEGF-treated grafts
relaxed in a dose-dependent manner to acetylcholine
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Fig. 2. Light micrographs of cross-sections taken from (A) normal external jugular vein, (B)
control vein graft, and (C) VEGF-treated vein graft. Lumen is at top. Arrow indicates border
between intima and media. Hematoxylin-eosin stain. All original magnifications, ´260.
Table I. Dimensional analysis of vein grafts
Control (n = 8) VEGF (n = 8) p
11.03 ± 0.34 12.44 ± 0.50 0.013
0.98 ± 0.06 0.76 ± 0.07 0.028
89 ± 5 62 ± 6 0.001
Vessel intimal circumference and intimal area were averaged from
the proximal, middle and distal segments of the vein grafts.
Intimal circumference
(mm)
Intimal area (mm2)
Intimal thickness (mm)
as well as manifesting greater maximal relaxation to
the receptor-independent, endothelium-dependent
agonist calcium ionophore A23187 compared with
control grafts. The superior relaxation response of
both control and VEGF-treated grafts to sodium
nitroprusside compared with normal veins may be
explained by a specific “supersensitivity” to nitrova-
sodilators in the setting of absent or impaired baseline
NO-mediated tone, as proposed by Moncada et al.36
Previous work has described endothelial surface
changes including altered morphologic characteris-
tics and denudation in a variety of circumstances in
autologous vein grafts. In this study, however, the
endothelium of the vein grafts appears relatively
intact as seen in vein grafts treated with Evans blue
and by scanning electron microscopy. Therefore, the
reduction in intimal hyperplasia seen here may not
be via the mechanism of reendothelialization, as was
evident in our previous rat carotid artery balloon
injury model.18 Instead, the endothelium of these
vein grafts likely undergoes “type I” injury in which
the endothelium is rendered dysfunctional while
remaining more or less morphologically intact.37
Thus the endothelium of vein grafts in the arterial
circulation, although morphologically similar to nor-
mal venous endothelium, appears to be functionally
impaired with regard to its vasomotor reactivity.
Although current surgical techniques of vein
grafting aim to minimize endothelial damage, an
unstable state is created in which both endothelial
and smooth muscle cell function are altered. The
processes that lead to intimal hyperplasia and the
changes in endothelial and smooth muscle cell phe-
notypes begin early after grafting into the arterial
circulation. Therefore, interventions that are
designed to control these lesions should be initiated
before or at the time of vein grafting. In this respect,
the intraoperative approach described here, which
involves only a short period of topical application
with no preimplant or postimplant administration,
may have considerable practical merit.
CONCLUSION
We demonstrated that simple immersion of vein
grafts in a solution containing the endothelial
cell–specific mitogen VEGF before implantation
reduces intimal hyperplasia and preserves endothelial
function in a rabbit vein graft model. Although the
exact mechanisms by which VEGF exerts its benefi-
cial effect cannot be fully addressed by this in vivo
study, its known effect on NO production appears to
be important. Further evaluation of this novel
approach to improving vein graft patency appears
warranted.
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